| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
69,133 |
99,133 |
200,384 |
249,340 |
| Total Sell Value |
$3,373,178 |
$4,809,278 |
$8,291,909 |
$10,478,837 |
| Total People Sold |
8 |
8 |
9 |
12 |
| Total Sell Transactions |
10 |
11 |
20 |
34 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kakkis Emil D |
President & CEO |
• • – |
2024-02-07 |
4 |
AS |
$45.00 |
$1,350,000 |
D/D |
(30,000) |
539,770 |
|
-1% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2024-01-02 |
4 |
OE |
$21.00 |
$63,000 |
D/D |
3,000 |
27,892 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2023-12-29 |
4 |
AS |
$47.87 |
$1,436,100 |
D/D |
(30,000) |
569,770 |
|
-7% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2023-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
24,614 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2023-10-23 |
4 |
S |
$32.78 |
$1,307,201 |
D/D |
(39,878) |
246,860 |
|
-67% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2023-10-23 |
4 |
OE |
$6.86 |
$273,563 |
D/D |
39,878 |
286,738 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2023-10-19 |
4 |
AS |
$33.52 |
$1,604,033 |
D/D |
(47,853) |
599,743 |
|
55% |
|
| Kakkis Emil D |
President & CEO |
• • – |
2023-10-19 |
4 |
OE |
$6.86 |
$328,272 |
D/D |
47,853 |
647,029 |
|
- |
|
| Horn Howard |
Chief Financial Officer |
• – – |
2023-10-09 |
4 |
A |
$0.00 |
$0 |
D/D |
80,366 |
80,336 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2023-09-07 |
4 |
AS |
$38.34 |
$88,249 |
D/D |
(2,163) |
23,614 |
|
6% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2023-09-07 |
4 |
OE |
$21.00 |
$42,000 |
D/D |
2,000 |
25,777 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2023-09-05 |
4 |
S |
$37.96 |
$227,760 |
D/D |
(6,000) |
51,281 |
|
-20% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2023-09-01 |
4 |
AS |
$37.04 |
$36,032 |
D/D |
(970) |
23,777 |
|
22% |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2023-06-30 |
4 |
AS |
$46.76 |
$27,355 |
D/D |
(585) |
8,985 |
|
-17% |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2023-06-19 |
4 |
S |
$48.20 |
$14,701 |
D/D |
(305) |
57,281 |
|
31% |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2023-06-08 |
4 |
AS |
$51.65 |
$76,700 |
D/D |
(1,485) |
9,570 |
|
-29% |
|
| Suliman Shehnaaz |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
14,855 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2023-06-07 |
4 |
D |
$51.82 |
$171,006 |
D/D |
(3,300) |
27,055 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
30,355 |
|
- |
|
| Ray Amrit |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
12,280 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
21,605 |
|
- |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
11,055 |
|
- |
|
| Narachi Michael |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
21,605 |
|
- |
|
| Dunsire Deborah |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860 |
19,730 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2023-05-18 |
4 |
AS |
$50.00 |
$100,600 |
D/D |
(2,012) |
74,744 |
|
-28% |
|
628 Records found
|
|
Page 2 of 26 |
|
|
0.45 (1.04%) 
